Market Analysis - Pharmacology 2019
More research in pharmacology deals with identifying and responding to drug interactions reactions and side effects and treat accordingly. It is useful to understand the process of drug intake, absorption, distribution, metabolism and elimination. More intensive study with the interaction between drug and its effect helps in identify the properties of ideal drugs and otherwise
Europe is one such region which encompasses the major share of the Pharmacology and Toxicology research. Spain being one of the most advanced European economies is bound to hold the chief share in Europe’s Pharmacology market. Further as EU expands the research, export and trading relations are bound to enhance.
Today, development of new drugs takes up to 15 years with average spending of more than $1 billion. Most drug discovery today is based on target identification and further screening for drug candidates. However, the efficiency of this approach is very low; in general, from thousands of compounds, only a number of candidates are identified and further developed as commercial drugs.
The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.
The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.
Pharmacology of vascular endothelium deals with alterations of endothelial cells and the vasculature play a central role in the pathogenesis of a broad spectrum of the most dreadful of human diseases, as endothelial cells have the key function of participating in the maintenance of patent and functional capillaries. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
The global in vitro toxicology testing market is expected to USD 27.36 Billion by 2021 from USD 14.15 Billion in 2016, at a CAGR of 14.1% between 2016 and 2021. Toxicity testing of new compounds is essential in drug development, as identifying the potential toxicity at an early stage in drug discovery can save both time and developmental costs, and also reduce the likelihood of late-stage failure.
Opposition to animal testing, new & promising technologies, increasing R&D to detect toxicity at early stages and insufficient databases to facilitate the use of in vitro test methods are driving factors of the in vitro toxicology testing market.
On the other hand lack of in vitro models to detect autoimmunity and immunostimulation and predictive ability of in vitro testing over in vivo testing are the major factor restraining the growth of this market.
The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
An overview of biopharmaceutical single-use technologies, which aid the manufacturing process in overcoming such complex issues as sterilization and critical manufacturing parameters. Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
A significant portion of R&D budgets are spent on outsourcing services (domestic and/or international) offered by the CRO industry, approximately $15 billion in 2007. This figure is expected to grow at 15% over the next seven years and should increase further with the broadening of the spectrum of services outsourced to cover the entire value chain. As outsourced services in developing countries such as China and India move up the value chain to cover phase 1/2 trials. The U.S insomnia market is categorised into pharmacological treatments and non-pharmacological treatments. The U.S. insomnia pharmacological treatment market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The duration of insomnia can be from a day to years. Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), and chronic insomnia (more than 6 months).
The drug discovery market can be broken down into seven segments: high-throughput screening, bioanalytical instruments for drug discovery, cell-based assays for drug discovery, proteomics drug discovery, genomics drug discovery, bioinformatics as a platform for drug discovery, and other (metabolomics-based technologies, combinatorial chemistry, systems biology, and nanotechnology products). Drug discovery is a complex process and represents a main component of the pharmaceutical industry. Today, development of new drugs takes up to 15 years with average spending of more than $1 billion. Most drug discovery today is based on target identification and further screening for drug candidates. However, the efficiency of this approach is very low; in general, from thousands of compounds, only a number of candidates are identified and further developed as commercial drugs.
Major Pharmacology Associations around the Globe
· American Academy of Veterinary Pharmacology and Therapeutics
· American Board of Clinical Pharmacology
· Argentine Society for Experimental Pharmacology
· Association of Pharmacologists of Ukraine
· Australian Physiological and Pharmacological Society
· British Association for Psychopharmacology
· Colombian Association of Pharmacology